Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Spark Therapeutics, Inc.
This study will follow patients with hemophilia A, who have received a single intravenous administration of SPK-8011 or SPK-8016 in any prior Spark-sponsored SPK-8011 or SPK-8016 study. Participants will be followed for up to a total of 10 years post infusion (including the time on the dosing study).
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Participants are eligible to be included in the study only if all of the following criteria apply:
1. Have received a single intravenous administration of SPK-8011 or SPK-8016 in either Study SPK-8011-101 or SPK-8016-101, respectively.
2. Understand the purpose and risks of the study and provide signed and dated informed consent before undergoing any study-specific procedures.
You may not be if
Participants are excluded from the study if any of the following criteria apply:
1.Unable or unwilling to comply with the schedule of visits and study assessments as described in this study protocol.
